×
About 2,720 results

ALLMedicine™ Hyperphosphatemia Center

Research & Reviews  864 results

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT04523727

Jun 21st, 2022 - This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

Pseudoxanthoma Elasticum Workup
https://emedicine.medscape.com/article/1074713-workup

Jun 20th, 2022 - Laboratory Studies Perform a CBC count to screen for iron deficiency anemia. Perform a fecal occult blood test to evaluate for GI bleeding. Perform a urinalysis to screen for urinary tract hemorrhage. Obtain serum lipid levels. Pseudoxanthoma elas...

The effect of egg white diet on phosphorus control in dialysis patients.
https://doi.org/10.1111/hdi.13028
Hemodialysis International. International Symposium on Ho... Azmandian J, Shamspour N et. al.

Jun 18th, 2022 - Nutritional interventions have been envisaged to improve hyperphosphatemia and malnutrition, two important risk factors associated with mortality in dialysis patients. We evaluated the effects of egg white consumption on serum phosphate and malnut...

Phosphate balance during dialysis and after kidney transplantation in patients with chr...
https://doi.org/10.1097/MNH.0000000000000802 10.3390/toxins12030189
Current Opinion in Nephrology and Hypertension; Duque EJ, Elias RM et. al.

Jun 16th, 2022 - In patients with chronic kidney disease (CKD), hyperphosphatemia is associated with several adverse outcomes, including bone fragility and progression of kidney and cardiovascular disease. However, there is a knowledge gap regarding phosphate bala...

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
https://clinicaltrials.gov/ct2/show/NCT04228042

Jun 10th, 2022 - PRIMARY OBJECTIVE: I. Evaluate the tolerability of infigratinib in patients with low-grade and high-grade platinum ineligible upper tract urothelial carcinoma (UTUC). SECONDARY OBJECTIVES: I. Assess tolerability in those with GFR 30-49. II. Evalua...

see more →

Drugs  16 results see all →

Clinicaltrials.gov  122 results

Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT04523727

Jun 21st, 2022 - This study will be conducted to assess the safety and tolerability of ferric citrate in pediatric participants with hyperphosphatemia related to chronic kidney disease (CKD).

Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
https://clinicaltrials.gov/ct2/show/NCT04228042

Jun 10th, 2022 - PRIMARY OBJECTIVE: I. Evaluate the tolerability of infigratinib in patients with low-grade and high-grade platinum ineligible upper tract urothelial carcinoma (UTUC). SECONDARY OBJECTIVES: I. Assess tolerability in those with GFR 30-49. II. Evalua...

mHealth for Phosphorus Management in CKD.
https://clinicaltrials.gov/ct2/show/NCT05389826

May 25th, 2022 - The working hypotheses are listed as follows: Hyperphosphatemia is an important problem in the CKD realm, but difficult to manage because patients are often not aware of its importance. In addition, current clinical practice does not allow nephrol...

Sodium Zirconium Cyclosilicate Lowers Hyperkalemia After Parathyroidectomy
https://clinicaltrials.gov/ct2/show/NCT05382988

May 19th, 2022 - Secondary Hyperparathyroidism (SHPT) is a common and severe manifestation of chronic kidney disease (CKD), especially in end-stage renal disease (ESRD) patients. SHPT is characterized by elevated parathyroid hormone (PTH) synthesis and secretion a...

Atorvastatin Effects On Arterial Stiffness In Hemodialysis
https://clinicaltrials.gov/ct2/show/NCT04472637

Apr 15th, 2022 - Cardiovascular disease (CVD) is the most common cause of morbidity and mortality among patients with end-stage renal disease (ESRD) on hemodialysis (HD). CVD are present since the early stages of chronic kidney disease (CKD) and reach around 30 to...

see more →

News  86 results

Long-Term Data Confirm Benefit of Erdafitinib in FGFR-Mutated Urothelial Carcinoma
https://www.onclive.com/view/long-term-data-confirm-benefit-of-erdafitinib-in-fgfr-mutated-urothelial-carcinoma

Jan 25th, 2022 - The FGFR TKI erdafitinib (Balversa) continued to provide consistent clinical benefits with a manageable safety profile when used in the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma harboring FGFR alter...

Pruritic Eruption on the Trunk and Extremities
https://www.mdedge.com/dermatology/article/250201/dermatopathology/pruritic-eruption-trunk-and-extremities
David Micah Milgraum, MD, Alexandra Rubin, MBS et. al.

Dec 23rd, 2021 - THE DIAGNOSIS: Acquired Perforating Disorder of Renal Disease A papule with the central plug removed left a pitlike depression, representing Kyrle disease (Figure 1). A punch biopsy of the left forearm revealed epidermal hyperplasia (Figure 2A) su.

Rapid Progress Made With Late-Line Therapies in Metastatic Urothelial Cancer
https://www.onclive.com/view/rapid-progress-made-with-late-line-therapies-in-metastatic-urothelial-cancer

Oct 6th, 2021 - With the emergence of immunotherapies, FGFR inhibitors, and antibody-drug conjugates (ADCs), the metastatic urothelial cancer treatment paradigm has dramatically evolved, according to Praful K. Ravi, MD, and even more approaches continue to emerge...

Erdafitinib Plus Cetrelimab Exhibits Encouraging Efficacy in Metastatic Urothelial Cancer
https://www.onclive.com/view/erdafitinib-plus-cetrelimab-exhibits-encouraging-efficacy-in-muc

Sep 22nd, 2021 - Erdafitinib (Balversa) in combination with cetrelimab (JNJ-63723283) displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma (mUC) harboring FGFR alterations, according to the first results fr...

FDA Rejects Tenapanor for Control of Phosphorus in Kidney Disease
https://www.medscape.com/viewarticle/956066

Aug 5th, 2021 - The US Food and Drug Administration (FDA) is asking for an additional clinical trial to demonstrate greater benefits of tenapanor before it can decide on approval of the drug for the control of serum phosphorus in adults with chronic kidney diseas...

see more →